Read by QxMD icon Read

gleason grades

Ji Eun Heo, Kyo Chul Koo, Sung Joon Hong, Sang Un Park, Byung Ha Chung, Kwang Suk Lee
PURPOSE: To evaluate parameters for determining repeat prostate biopsy in patients with 5α-reductase inhibitor (5ARI) treatment after initial negative biopsy. MATERIALS AND METHODS: From January 2007 to December 2015, patients who underwent a repeat prostate biopsy after an initial negative biopsy were enrolled from multiple institutions. Serial prostate-specific antigen (PSA) levels after the initial biopsy were analyzed for PSA kinetics. Clinicopathologic variables were evaluated according to the use of 5ARIs after the initial negative biopsy...
March 2018: Yonsei Medical Journal
James T Kearns, Anna V Faino, Lisa F Newcomb, James D Brooks, Peter R Carroll, Atreya Dash, William J Ellis, Michael Fabrizio, Martin E Gleave, Todd M Morgan, Peter S Nelson, Ian M Thompson, Andrew A Wagner, Yingye Zheng, Daniel W Lin
BACKGROUND: Many patients who are on active surveillance (AS) for prostate cancer will have surveillance prostate needle biopsies (PNBs) without any cancer evident. OBJECTIVE: To define the association between negative surveillance PNBs and risk of reclassification on AS. DESIGN, SETTING, AND PARTICIPANTS: All men were enrolled in the Canary Prostate Active Surveillance Study (PASS) between 2008 and 2016. Men were included if they had Gleason ≤3+4 prostate cancer and <34% core involvement ratio at diagnosis...
February 9, 2018: European Urology
Mohammed Ibrahim, Siddhartha Yadav, Foluso Ogunleye, Dana Zakalik
BACKGROUND: Mutations in BRCA1 and BRCA2 (BRCA1/2) genes are associated with an increased risk of breast and ovarian cancers in women. The cancer characteristics of men with BRCA1/2 mutations are less well studied. This study describes the unique cancer characteristics of male BRCA1/2 mutation carriers at our institution. METHODS: We performed a retrospective chart review on male patients who were seen between January 2004 and December 2014 and tested positive for a BRCA1/2 mutation...
February 13, 2018: BMC Cancer
Giorgio I Russo, Sebastiano Cimino, Giorgia Giranio, Federica Regis, Vincenzo Favilla, Salvatore Privitera, Fabio Motta, Rosario Caltabiano, Arnulf Stenzl, Tilman Todenhöfer, Giuseppe Morgia
INTRODUCTION AND OBJECTIVES: To evaluate the association between metabolic syndrome (MetS) and proliferative inflammatory atrophy (PIA) in patients with suspected prostate cancer (PCa). PATIENTS AND METHODS: From June 2015 to July 2016, we conducted the FIERY (Flogosis Increased Events of pRostatic biopsY) study at the Urology section, Department of Surgery of the University of Catania (Local registration number: #131/2015). A total of 205 patients with elevated prostate-specific antigen (≥ 4 ng/ml) or clinical suspicion of PCa who underwent primary transperineal prostate biopsy were included in this cross-sectional study...
February 8, 2018: Urologic Oncology
Michelle L McDonald, Lauren E Howard, William J Aronson, Martha K Terris, Matthew R Cooperberg, Christopher L Amling, Stephen J Freedland, Christopher J Kane
OBJECTIVE: To analyze factors associated with metastases, prostate cancer-specific mortality, and all-cause mortality in pN1 patients. MATERIALS AND METHODS: We analyzed 3,642 radical prostatectomy patients within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Pathologic Gleason grade, number of lymph nodes (LN) removed, and first postoperative prostate-specific antigen (PSA) (<0.2 ng/ml or ≥0.2 ng/ml) were among covariates assessed. Cox regression was used to analyze the association between characteristics and survival outcomes...
February 8, 2018: Urologic Oncology
S Brunelle, C Zemmour, F Bratan, F Mège-Lechevallier, A Ruffion, M Colombel, S Crouzet, A Sarran, O Rouvière
PURPOSE: To evaluate the variability induced by the imager in discriminating high-grade (Gleason≥7) prostate cancers (HGC) using dynamic contrast-enhanced MRI. MATERIAL AND METHODS: We retrospectively selected 3T MRIs with temporal resolution<10 seconds and comprising T1 mapping from a prospective radiologic-pathologic database of patients treated by prostatectomy. Ktrans, Kep, Ve and Vp were calculated for each lesion seen on MRI using the Weinmann arterial input function (AIF) and three patient-specific AIFs measured in the right and left iliac arteries in pixels in the center of the lumen (psAIF-ST) or manually selected by two independent readers (psAIF-R1 and psAIF-R2)...
February 7, 2018: Diagnostic and Interventional Imaging
Andrea Hinsch, Meta Brolund, Claudia Hube-Magg, Martina Kluth, Ronald Simon, Christina Möller-Koop, Guido Sauter, Stefan Steurer, Andreas Luebke, Alexander Angerer, Corinna Wittmer, Emily Neubauer, Cosima Göbel, Franziska Büscheck, Sarah Minner, Waldemar Wilczak, Thorsten Schlomm, Frank Jacobsen, Till Sebastian Clauditz, Till Krech, Maria Christina Tsourlakis, Cornelia Schroeder
BACKGROUND: IDH1 mutations are oncogenic through induction of DNA damage and genome instability. They are of therapeutic interest because they confer increased sensitivity to radiation and cytotoxic therapy and hold potential for vaccination therapy. METHODS: In this study, we analyzed more than 17,000 primary prostate cancer tissues with a mutation-specific antibody for the IDH1R132H mutation. RESULTS: IDH1 mutation-specific staining was found in 42 of 15,531 (0...
February 9, 2018: World Journal of Urology
Donna P Ankerst, Martin Goros, Scott A Tomlins, Dattatraya Patil, Ziding Feng, John T Wei, Martin G Sanda, Jonathan Gelfond, Ian M Thompson, Robin J Leach, Michael A Liss
BACKGROUND: The Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) is a commonly used risk tool for predicting the outcome on biopsy based on the established risk factors. OBJECTIVE: To determine whether incorporation of the novel urinary markers prostate cancer antigen 3 (PCA3) and TMPRSS2:ERG (T2:ERG) into the PCPTRC improves its discrimination, accuracy, and clinical net benefit. DESIGN, SETTING, AND PARTICIPANTS: Since PCA3 and T2:ERG were not measured as part of the PCPTRC, a Bayesian modeling approach was used to combine data where the markers were measured in a Michigan cohort with the PCPTRC as prior probabilities to form an updated PCPTRC...
February 5, 2018: European Urology Focus
Richard K Valicenti, Stephanie L Pugh, Edouard J Trabulsi, Oliver Sartor, Eric C Ko, Michael R Girvigian, Seth A Rosenthal, Mark E Shaves, Jeannie H Hoffman-Censits, John Schallenkamp, Howard M Sandler
PURPOSE: To investigate the utility of 153Sm lexidronam (Quadramet) in the setting of men with prostate cancer status post radical prostatectomy who develop biochemical failure with no clinical evidence of osseous metastases. PATIENTS AND METHODS: Trial NRG Oncology RTOG 0622 is a single-arm phase 2 trial that enrolled men with pT2-T4, N0-1, M0 prostate cancer status post radical prostatectomy, who meet at least 1 of these biochemical failure criteria: (1) prostate-specific antigen (PSA) > 1...
March 1, 2018: International Journal of Radiation Oncology, Biology, Physics
Wei Liu, Xiao H Liu, Wei Tang, Hong B Gao, Bing N Zhou, Liang P Zhou
BACKGROUND: Noninvasive measures to evaluate the aggressiveness of prostate carcinoma (PCa) may benefit patients. PURPOSE: To assess the value of stretched-exponential and monoexponential diffusion-weighted imaging (DWI) for predicting the aggressiveness of PCa. STUDY TYPE: Retrospective study. SUBJECTS: Seventy-five patients with PCa. FIELD STRENGTH: 3T DWI examinations were performed using b-values of 0, 500, 1000, and 2000 s/mm2 ...
February 7, 2018: Journal of Magnetic Resonance Imaging: JMRI
Susan Prendeville, Mark Gertner, Manjula Maganti, Melania Pintilie, Nathan Perlis, Ants Toi, Andrew J Evans, Antonio Finelli, Theodorus H van der Kwast, Sangeet Ghai
PURPOSE: The aim of this study was to compare biopsy detection of intraductal (IDC) and cribriform (CR) pattern invasive prostate carcinoma (PCa) in mpMRI positive and negative regions of the prostate. MATERIAL AND METHODS: A prospectively maintained single institution database was queried to identify patients who underwent mpMRI/US fusion targeted biopsy (MRI-TBx) and concurrent systematic sextant biopsy of MRI negative regions (SMN-Bx) between January 2013 and May 2016...
January 31, 2018: Journal of Urology
Cosimo De Nunzio, Antonio Luigi Pastore, Riccardo Lombardo, Giuseppe Simone, Costantino Leonardo, Riccardo Mastroianni, Devis Collura, Giovanni Muto, Michele Gallucci, Antonio Carbone, Andrea Fuschi, Lorenzo Dutti, John H Witt, Carlo De Dominicis, Andrea Tubaro
PURPOSE: To evaluate the differences between the old and the new Gleason score classification systems in upgrading and downgrading rates. MATERIALS AND METHODS: Between 2012 and 2015, we identified 9703 patients treated with retropubic radical prostatectomy (RP) in four tertiary centers. Biopsy specimens as well as radical prostatectomy specimens were graded according to both 2005 Gleason and 2014 ISUP five-tier Gleason grading system (five-tier GG system). Upgrading and downgrading rates on radical prostatectomy were first recorded for both classifications and then compared...
January 9, 2018: European Journal of Surgical Oncology
Anouk A M A van der Aa, Christophe K Mannaerts, Hans van der Linden, Maudy Gayet, Bart Ph Schrier, Massimo Mischi, Harrie P Beerlage, Hessel Wijkstra
PURPOSE: To determine the value of a three-dimensional (3D) greyscale transrectal ultrasound (TRUS)-guided prostate biopsy system and biopsy core pre-embedding method on concordance between Gleason scores of needle biopsies and radical prostatectomy (RP) specimens. METHODS: Retrospective analysis of prostate biopsies and subsequent RP for PCa in the Jeroen Bosch Hospital, the Netherlands, from 2007 to 2016. Two cohorts were analysed: conventional 2D TRUS-guided biopsies and RP (2007-2013, n = 266) versus 3D TRUS-guided biopsies with pre-embedding (2013-2016, n = 129)...
February 1, 2018: World Journal of Urology
Samuel W D Merriel, Margaret T May, Richard M Martin
INTRODUCTION: Prostate cancer is the most common cancer in men in the UK, with nearly 40 000 diagnosed in 2014; and it is the second most common cause of male cancer-related mortality. The clinical conundrum is that most men live with prostate cancer rather than die from it, while existing treatments have significant associated morbidity. Recent studies have shown very low mortality rates (1% after a median of 10-year follow-up) and no treatment-related reductions in mortality, in men with localised prostate cancer...
January 31, 2018: BMJ Open
Hua-Chun Luo, Zhi-Chao Fu, Hui-Hua Cheng, Yong Lei, Shao-Guang Liao, Jing Feng, Qin Yin, Qun-Hua Chen, Gui-Shan Lin, Jin-Feng Zhu, Jian-Feng Xu, Wang Dian
How to define a clinical target volume (CTV) as small as possible for prostate cancer to reduce the dose received by normal organs is an interesting study. We conduct a research to analyze the clinical efficacy of intensity modulated radiotherapy (IMRT) using reduced CTV in the treatment of prostate cancer. From January 2006 to June 2010, 78 patients with prostate cancer were treated with IMRT according to this institutional protocol. Of them, 18 had stage II tumors, 39 had stage III tumors, and 21 had stage IVa tumors...
December 2017: Medicine (Baltimore)
Stephanie Tanadini-Lang, Marta Bogowicz, Patrick Veit-Haibach, Martin Huellner, Chantal Pauli, Vyoma Shukla, Matthias Guckenberger, Oliver Riesterer
BACKGROUND/AIM: An evaluation if radiomic features of CT perfusion (CTP) can predict tumor grade and aggressiveness in prostate cancer was performed. MATERIALS AND METHODS: Forty-seven patients had biopsy-confirmed prostate cancer, and received a CTP. Blood volume (BV), blood flow (BF) and mean transit time (MTT) maps were derived and 1,701 radiomic features were determined per patient. Regression models were built to estimate post-surgical Gleason score (GS), microvessel density (MVD) and distinguish between the different risk groups...
February 2018: Anticancer Research
Wen-Jun Xiao, Yu Zhu, Yao Zhu, Bo Dai, Ding-Wei Ye
OBJECTIVES: This study aimed to evaluate the eighth edition of the American Joint Committee on Cancer (AJCC) for clinical staging of prostate cancer based upon Surveillance, Epidemiology and, End Results (SEER) database. MATERIALS AND METHODS: Patients diagnosed as prostate adenocarcinoma during 2004-2009 without any surgical treatment to the primary site were selected from the SEER registry. Excluded were cases with incomplete or unavailable staging, PSA and Gleason score information...
January 25, 2018: World Journal of Urology
Christoph Würnschimmel, Pietro Grande, Marco Moschini, Matteo Ferrari, Livio Mordasini, Agostino Mattei
OBJECTIVE: To evaluate the effectiveness of EAU Guideline compliant transrectal ultrasound-guided 12-core prostate biopsies for detection of highly aggressive Epstein Grade 5 (Gleason Score 9-10) prostate cancer. METHODS: Two hundred ninety-nine patients, treated by radical prostatectomy for prostate cancer, have been prospectively recorded in a database and were evaluated for this study. Pre-operatively, all patients received transrectal ultrasound-guided biopsies according to inhomogeneous templates chosen by the referring urologist...
January 25, 2018: Prostate
Pedro Isaacsson Velho, John L Silberstein, Mark C Markowski, Jun Luo, Tamara L Lotan, William B Isaacs, Emmanuel S Antonarakis
BACKGROUND: Germline mutations in genes mediating DNA repair are common in men with recurrent and advanced prostate cancer, and their presence may alter prognosis and management. We aimed to define pathological and clinical characteristics associated with germline DNA-repair gene mutations, to facilitate selection of patients for germline testing. METHODS: We retrospectively evaluated 150 unselected patients with recurrent or metastatic prostate cancer who were offered germline genetic testing by a single oncologist using a clinical-grade assay (Color Genomics)...
January 25, 2018: Prostate
Pat F Fulgham
PURPOSE: The purpose this study is to evaluate the efficacy of multiparametric ultrasound-targeted biopsies in patients undergoing initial biopsy of the prostate for the suspicion of prostate cancer. MATERIALS AND METHODS: A total of 167 patients who are biopsy naïve underwent multiparametric ultrasound-targeted biopsy of the prostate. All patients had a transrectal ultrasound which included gray-scale evaluation and color Doppler evaluation. 12-core biopsies were performed on all patients, based on sextant anatomy; however, all cores were directed toward visually abnormal areas of the prostate as identified by multiparametric ultrasound, when such areas were present...
January 24, 2018: World Journal of Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"